{"id":7382,"date":"2026-06-20T02:38:39","date_gmt":"2026-06-20T02:38:39","guid":{"rendered":"https:\/\/gothi.gov.eg\/?page_id=7382"},"modified":"2026-06-20T02:42:58","modified_gmt":"2026-06-20T02:42:58","slug":"%d8%b7%d8%a8-%d8%ba%d8%af%d8%af-%d8%b5%d9%85%d8%a7%d8%a1-%d9%88%d8%b3%d9%83%d8%b1%d9%8a","status":"publish","type":"page","link":"https:\/\/gothi.gov.eg\/?page_id=7382","title":{"rendered":"\u0637\u0628 \u063a\u062f\u062f \u0635\u0645\u0627\u0621 \u0648\u0633\u0643\u0631\u064a"},"content":{"rendered":"\t\t
\n\t\t\t\t
\n\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t\n
    \n
  1. <\/li>\n<\/ol>\n\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t
    \n\t\t\t\t\t
    \n\t\t\t\t
    \n\t\t\t\t
    \n\t\t\t\t\t

    \u0637\u0628 \u063a\u062f\u062f \u0635\u0645\u0627\u0621 \u0648\u0633\u0643\u0631\u064a\n<\/h2>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t
    \n\t\t\t\t
    \n\t\t\t\t\t
    \n\n
    \n\n
    \n\n \n\n \n <\/path><\/svg> <\/span>\n\n \n <\/path><\/svg> <\/span>\n \n <\/span>\n \n \n Glycemic Targets <\/span>\n\n <\/h5>\n\n
    \n
    \n
    \n
    \n
    “last update: 30 April 2024”\u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0<\/strong>Download Guideline<\/strong><\/u><\/a>
    <\/span><\/u><\/h5>\n<\/div>\n<\/div>\n<\/div>\n
    \n
    \n
    \n
    \u00a0<\/div>\n<\/div>\n<\/div>\n<\/div>\n
    \n

    – Executive Summary<\/h3>\n
    \n

    \u00a0<\/p>\n

    This guideline offers evidence-based recommendations on the targeted levels of blood glucose. The recommendations are intended to provide healthcare professionals with practical guidance on monitoring of blood glucose and improving health outcomes for people living with Diabetes.<\/span><\/p>\n\n\n\n\n
    \n

    Recommendations<\/span><\/h4>\n

    \u00a0<\/h1>\n<\/td>\n<\/tr>\n

    \n

    l\u00a0\u00a0<\/span>Glycemic status should be assessed at least twice a year using HbA1c and\/or suitable continuous glucose monitoring (CGM) parameters. Individuals who are not fulfilling treatment objectives, have frequent or severe hypoglycemia or hyperglycemia, have fluctuating health status, or are growing and developing in adolescence should be assessed more regularly (every three months).<\/span>\u00a0(<\/span>Good practice statement)<\/span><\/b><\/p>\n

    l\u00a0\u00a0<\/span>Glycemic status should be assessed at least quarterly and as needed in people whose therapy has recently changed and\/or who are not achieving their glycemic targets.\u00a0(Good practice statement)<\/b><\/span><\/p>\n

    l\u00a0\u00a0<\/span>An HbA1c target for many nonpregnant adults of <7% without significant hypoglycemia is recommended.\u00a0(strong recommendation)<\/b><\/span><\/p>\n

    l\u00a0\u00a0<\/span>Time in range is associated with the risk of microvascular complications and can be used for assessment of glycemic control. Additionally, time below range and time above range are useful parameters for the evaluation of the treatment plan. \u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 \u00a0\u00a0\u00a0(Conditional recommendation).<\/b><\/span><\/p>\n

    l\u00a0\u00a0<\/span>If using an ambulatory glucose profile\/glucose management indicator to assess glycemia, a parallel goal for many nonpregnant adults is TIR >70% with time below range <4% and time <54 mg\/dL <1%. For those with frailty or at high risk of hypoglycemia, a goal of >50% TIR with <1% time below range is recommended.\u00a0(Conditional recommendation).<\/b><\/span><\/p>\n

    l\u00a0\u00a0<\/span>On the basis of health care professional judgment and patient preference, achievement of lower HbA1c levels than the goal of 7% may be acceptable and even beneficial if it can be achieved safely without significant hypoglycemia or other adverse effects of treatment.\u00a0 (Strong recommendation)<\/b><\/span><\/p>\n

    l\u00a0\u00a0<\/span>Less stringent HbA1c targets (such as <8% may be appropriate for patients with limited life expectancy or where the harms of treatment are greater than the benefits.\u00a0(Strong recommendation)<\/b>.<\/b><\/span><\/p>\n

    l\u00a0\u00a0<\/span>Healthcare professionals should consider deintensification of therapy if appropriate to reduce the risk of hypoglycemia in patients with inappropriate stringent HbA1c targets.\u00a0\u00a0(Strong recommendation).<\/b><\/span><\/b><\/p>\n<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n
    \n

    \u00a0<\/p>\n<\/div>\n<\/div>\n

    \n
    \n
    \n
    \u00a0<\/div>\n<\/div>\n
    \n
    \n
    \u00a0<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div> <\/div>\n\n <\/div>\n
    \n\n
    \n\n \n\n \n <\/path><\/svg> <\/span>\n\n \n <\/path><\/svg> <\/span>\n \n <\/span>\n \n \n Prevention or Delay of Type 2 Diabetes Mellitus <\/span>\n\n <\/h5>\n\n
    \n
    \n
    \n
    \n
    “last update: 14 February 2024”\u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0\u00a0\u00a0\u00a0\u00a0<\/span>\u00a0Download Guideline<\/u><\/a><\/strong><\/h5>\n<\/div>\n<\/div>\n<\/div>\n
    \n
    \n
    \n
    \u00a0<\/div>\n<\/div>\n<\/div>\n<\/div>\n
    \n

    – Executive Summary<\/h3>\n
    \n

    \u00a0<\/p>\n

    The prevalence of diabetes is globally increasing with a high incidence of complications. Targeted interventions and support are important in this high-risk group. Globally, more than 570 million adults live with diabetes so Prevention or delay of type 2 diabetes Mellitus (T2DM) is of great importance.<\/span><\/p>\n

    This guideline offers evidence-based recommendations for the prevention of diabetes. The recommendations are intended to provide healthcare professionals with practical guidance on preventing or delaying diabetes and associated co-morbidities improving healthy lifestyles for people with high risk of type 2 diabetes.<\/span><\/p>\n

    \u00a0<\/span><\/p>\n\n\n\n\n
    \n
    Recommendations<\/strong><\/span><\/h5>\n

    \u00a0<\/h1>\n<\/td>\n<\/tr>\n

    \n

    l\u00a0\u00a0<\/span>Refer adults with overweight\/obesity at high risk of type 2 diabetes, to an intensive lifestyle behavior change program for a weight reduction of at least 7% of initial body weight through a healthy reduced-calorie diet and 150 min\/week of moderate-intensity physical activity.\u00a0(Strong recommendation)<\/strong>.<\/span><\/p>\n

    l\u00a0\u00a0<\/span>A variety of eating patterns should be considered to prevent diabetes in individuals with prediabetes. Including Mediterranean diet, low carbohydrate eating plan, low fat, DASH diet (Dietary approaches to stop hypertension)\u00a0(Strong recommendation)<\/strong><\/span><\/p>\n

    l\u00a0\u00a0<\/span>Prescribe metformin for\u00a0<\/span>prevention\u00a0<\/span>of T2DM in adult individuals with prediabetes, 25-59 years, those with high BMI \u226535 kg\/m2, higher fasting plasma glucose 100 – 125 mg\/dL, higher HbA1C 5.7 \u2013 6.4%, women with prior GDM\u00a0\u00a0\u00a0(strong recommendation)<\/strong><\/span><\/p>\n

    l\u00a0\u00a0<\/span>Prediabetes is associated with heightened cardiovascular risk; therefore, screening for and treatment of modifiable risk factors for cardiovascular disease should be considered.\u00a0(Strong recommendation)<\/strong><\/span><\/p>\n

    l\u00a0\u00a0<\/span>More intensive preventive approaches should be considered in individuals who are at particularly high risk of progression to diabetes, including individuals with BMI \u226535 kg\/m2, those at higher glucose levels (e.g., fasting plasma glucose 100 \u2013125 mg\/dL, 2-h postprandial glucose 140 \u2013 199 mg\/dL, A1C 5.7 \u2013 6.4%), and individuals with a history of gestational diabetes mellitus\u00a0(strong recommendation)<\/strong><\/span><\/p>\n

    l\u00a0\u00a0<\/span>Pharmacotherapy should be considered to achieve sustained weight loss<\/span>,<\/span>\u00a0minimize the progression of hyperglycemia, and cardiovascular risk reduction.\u00a0<\/span>(strong recommendation)<\/span><\/strong><\/p>\n<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n
    \n

    \u00a0<\/p>\n<\/div>\n<\/div>\n

    \n
    \n
    \n
    \u00a0<\/div>\n<\/div>\n
    \n
    \n